A Study of ASC50 Tablets for Plaque Psoriasis
This study is testing a new medication called ASC50 tablets for people with plaque psoriasis, as well as healthy volunteers. Researchers want to understand if ASC50 is safe, how well your body handles it, and if it helps with psoriasis. You might receive ASC50 tablets or a placebo (an inactive pill that looks the same). The main way researchers will know if the study is successful is by tracking any side effects you might experience. The study is open to adults aged 18 to 65 years old. The current recruitment status is unclear, but the study plans to enroll 94 participants.
- Study design
- This is a Phase 1, randomized, double-blind, placebo-controlled study involving single and multiple doses. It plans to enroll 94 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety will be monitored for up to 43 days after starting the study.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Adverse EventsUp to Day 7
Evaluate the incidence of Serious Adverse Events (SAEs) and Adverse Events (AEs)
- Adverse EventsUp to Day 43
Evaluate the incidence of Serious Adverse Events (SAEs) and Adverse Events (AEs)